No Data
Pyxis Oncology Coverage Assumed by Jefferies at Buy
Pyxis Oncology Coverage Assumed by Jefferies at Buy
Jefferies Investment Bank: Assuming Pyxis Oncology (PYXS.US) rating, adjusted from buy to buy rating, target price is $10.00.
Jefferies Investment Bank: Assuming Pyxis Oncology (PYXS.US) rating, adjusted from buy to buy rating, target price is $10.00.
Jefferies Assumes Pyxis Oncology at Buy, Announces Price Target of $10
Jefferies analyst Farzin Haque assumes Pyxis Oncology (NASDAQ:PYXS) with a Buy rating and announces Price Target of $10.
HROW, HCAT and EGRX Are Among After Hour Movers
Buy Rating Affirmed for Pyxis Oncology as PYX-201 Showcases Promising Preclinical Data and Broad Therapeutic Potential
Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Pyxis Oncology (PYXS – Research Report), retaining the price target of $7.00.
HC Wainwright & Co. : Pyxis Oncology (PYXS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $7.00.
HC Wainwright & Co. : Pyxis Oncology (PYXS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $7.00.